对于本土创新药而言,BD(商业拓展)已经成为企业战略布局的重要一环。 10月17日,翰森制药集团有限公司 (翰森制药,03692.HK)宣布,已与罗氏(Roche)就HS-20110签署许可协议。HS-20110是一款采用经临床验证的拓扑异构酶抑制剂(TOPOi)载荷的靶向CDH17抗体药物偶联物(ADC)。翰森制药授予罗氏在全球范围内(不含中国内地、香港、澳门和台湾)推进HS-20110开发及...
Source Link对于本土创新药而言,BD(商业拓展)已经成为企业战略布局的重要一环。 10月17日,翰森制药集团有限公司 (翰森制药,03692.HK)宣布,已与罗氏(Roche)就HS-20110签署许可协议。HS-20110是一款采用经临床验证的拓扑异构酶抑制剂(TOPOi)载荷的靶向CDH17抗体药物偶联物(ADC)。翰森制药授予罗氏在全球范围内(不含中国内地、香港、澳门和台湾)推进HS-20110开发及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.